ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia

Cell Biology International

Volumn 36, Issue 1, 2012, Pages 79-86

  Semsei, Agnes F ^a   Erdelyi, Daniel J ^a   Ungvari, Ildiko ^a   Csagoly, Edit ^a   Hegyi, Marta Z ^a   Kiszel, Petra S ^a   Lautner Csorba, Orsolya ^a   Szabolcs, Judit ^a   Masat, Peter ^b   Fekete, Gyorgy ^a   Falus, Andras ^a   Szalai, Csaba ^c,d,e   Kovacs, Gabor T ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Markusovszky Teaching Hospital   (Hungary)

^c HEIM PÁL CHILDREN S HOSPITAL   (Hungary)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^e Csertex Research Laboratory   (Hungary)

Author keywords

ABCC1; Cardiotoxicity; Fractional shortening; Leukaemia; Pharmacogenetics; Side effects

Indexed keywords

ANTHRACYCLINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; ATP BINDING CASSETTE SUBFAMILY C MEMBER 1 GENE; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRESCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ALLELES; ANTHRACYCLINES; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEART VENTRICLES; HUMANS; INFANT; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; VENTRICULAR FUNCTION, LEFT;

EID: 84862565294     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20110264     Document Type: Article

References (27)

1. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 2005;44:600-6.
2. Bakos E, Homolya L. Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch 2007;453:621-41.
3. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
4. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, Margulies EH et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007;447:799-816.
5. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-302.
6. Couture L, Nash JA, Turgeon J. Role of ATP-binding cassette transporters in drug distribution to the heart and protection from toxic compounds. Heart Metab 2007;35:16-21.
7. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol 2005;23:7685-96.
8. Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 2007;26:183-201.
9. Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio MT, Calabro R. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Paediatr Drugs 2005;7:67-76.
10. Johnson SA, Richardson DS. Anthracyclines in haematology: pharmacokinetics and clinical studies. Blood Rev 1998;12:52-71.
11. Jungsuwadee P, Nithipongvanitch R, Chen Y, Oberley TD, Butterfield DA, St Clair DK et al. Mrp1 localization and function in cardiac mitochondria after doxorubicin. Mol Pharmacol 2009;75:1117-26.
12. Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001;2:51-64.
13. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002;13:819-29.
14. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003;22:7537-52.
15. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629-36.
16. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008;94:525-33.
17. Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood 2008;111:5515-23.
18. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. Br Med J 2009;339:b4606.
19. Scully RE, Lipshultz SE. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc Toxicol 2007;7:122-8.
20. Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008;121:e387-96.
21. Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs 2005;7:187-202.
22. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Update 2003;6:71-84.
23. Viale PH, Yamamoto DS. Cardiovascular toxicity associated with cancer treatment. Clin J Oncol Nurs 2008;12:627-38.
24. Wang H, Jin G, Liu G, Qian J, Jin L, Wei Q et al. Genetic susceptibility of lung cancer associated with common variants in the 39 untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export. Cancer 2009;115:595-607.
25. Wang Z, Sew PH, Ambrose H, Ryan S, Chong SS, Lee EJ et al. Nucleotide sequence analyses of the MRP1 gene in four populations suggest negative selection on its coding region. BMC Genomics 2006;7:111.
26. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-62.
27. Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K. Anthracyclineinduced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention - review of the literature. Med Sci Monit 2000;6:411-20.